Schweta Arakali, MD
Allergy · Allentown, PANPI 1881024891
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 528 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.
Across 528 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$993
- GSK$966
- Takeda Pharmaceuticals U.S.A., Inc.$623
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$250%
- Food & beverage$11,73698%
- Education$2222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 66 | $2,043 |
| AstraZeneca | 90 | $2,028 |
| Regeneron Healthcare Solutions, Inc. | 45 | $1,199 |
| CSL Behring | 38 | $993 |
| GSK | 64 | $966 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $623 |
| Biocryst US Sales Co., LLC | 20 | $456 |
| Novartis | 20 | $386 |
| Optinose US, Inc. | 16 | $286 |
| Pfizer | 18 | $272 |
| Genentech USA, Inc. | 12 | $270 |
| Kaleo, Inc. | 18 | $256 |
| Covis Pharma GmbH | 12 | $252 |
| Blueprint Medicines Corporation | 9 | $235 |
| Alk-abello, Inc | 13 | $226 |
| Aimmune Therapeutics, Inc. | 10 | $221 |
| Amgen | 9 | $205 |
| Grifols USA, LLC | 9 | $188 |
| Sanofi-aventis U.S. LLC | 3 | $149 |
| Pharming Healthcare, Inc. | 5 | $116 |
| Boehringer Ingelheim | 5 | $109 |
| Bio Products Laboratory USA, Inc. | 4 | $58 |
| LEO Pharma Inc. | 2 | $50 |
| Aytu Biopharma, Inc. | 3 | $48 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $45 |
| Greer Laboratories, Inc. | 2 | $41 |
| Biofire Diagnostics, LLC | 1 | $41 |
| Mylan Specialty L.p. | 2 | $40 |
| Phadia US Inc. | 2 | $33 |
| USWM, LLC | 1 | $27 |
| AbbVie | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,983 in reported general payments places this provider in the 80th percentile of 25 allergy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 11 | $9,623 |
| Epinephrine | 13 | $3,758 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,190 |
| Ipratropium Bromide | 29 | $1,566 |
| Montelukast Sodium | 25 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $109 | $9,62311 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $3,75813 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $19 | $2,19011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 25 allergy providers in Pennsylvania.
Other allergy in Allentown
- Neil FeldmanAllentown$3K
- Michael PalumboPittsburgh$561K
- James DeangeloPittsburgh$79K
- Shannon KearneyBethlehem$48K
- Rehan MujahidWind Gap$16K
- Michelle WeissYork$7K
- David MillerPittsburgh$7K
- Andrew MurphyWest Chester$6K
- Victoria CorreaDoylestown$3K
- Thomas MakinWexford$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.